22 May 2013
Keywords: busy, period, aventis, firm, drops, ad, compound
Article | 08 March 2000
Aventis Pharma is terminating its development program forpropentofylline in the treatment of Alzheimer's disease, saying that
"the decision is a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 March 2000
© 2013 thepharmaletter.com